Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).

Khoury, Paneez; Akuthota, Praveen; Ackerman, Steven J; Arron, Joseph R; Bochner, Bruce S; Collins, Margaret H; Kahn, Jean-Emmanuel; Fulkerson, Patricia C; Gleich, Gerald J; Gopal-Srivastava, Rashmi; Jacobsen, Elizabeth A; Leiferman, Kristen M; Francesca, Levi-Schaffer; Mathur, Sameer K; Minnicozzi, Michael; Prussin, Calman; Rothenberg, Marc E; Roufosse, Florence; Sable, Kathleen; Simon, Dagmar; ... (2018). Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). Journal of leukocyte biology, 104(1), pp. 69-83. Society for Leukocyte Biology 10.1002/JLB.5MR0118-028R

[img] Text
Simon_Revisiting the NIH.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (358kB) | Request a copy

BACKGROUND Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. METHODS Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RESULTS RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. CONCLUSIONS Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Dagmar and Simon, Hans-Uwe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0741-5400

Publisher:

Society for Leukocyte Biology

Language:

English

Submitter:

Jana Berger

Date Deposited:

04 Jun 2018 11:02

Last Modified:

23 Jun 2018 01:32

Publisher DOI:

10.1002/JLB.5MR0118-028R

PubMed ID:

29672914

Uncontrolled Keywords:

biomarkers eosinophil-related disorders eosinophilia hypereosinophilic syndromes murine models translational research

BORIS DOI:

10.7892/boris.116903

URI:

https://boris.unibe.ch/id/eprint/116903

Actions (login required)

Edit item Edit item
Provide Feedback